Comments on: Is FDA Watching YouTube? http://blog.pharmexec.com/2008/10/10/is-fda-watching-youtube/ The Business of Pharmaceuticals Fri, 20 Aug 2010 10:09:38 -0400 hourly 1 By: Watching YouTube » FDA is Watching YouTube for Illegal Drug Advertising http://blog.pharmexec.com/2008/10/10/is-fda-watching-youtube/comment-page-1/#comment-24924 Watching YouTube » FDA is Watching YouTube for Illegal Drug Advertising Mon, 09 Mar 2009 02:33:43 +0000 http://blog.pharmexec.com/?p=302#comment-24924 [...] from the PhamaExec Blog: “Shire [ a drug company] received a warning letter for posting a sponsored testimonial on [...] [...] from the PhamaExec Blog: “Shire [ a drug company] received a warning letter for posting a sponsored testimonial on [...]

]]> By: James Robertson http://blog.pharmexec.com/2008/10/10/is-fda-watching-youtube/comment-page-1/#comment-16311 James Robertson Sat, 18 Oct 2008 15:45:59 +0000 http://blog.pharmexec.com/?p=302#comment-16311 As a matter of policy, just to avoid some unintended consequences of what employees might put of these social networking sites, I suggest that their IT departments block access from computers inside the organization's network. As a matter of policy, just to avoid some unintended consequences of what employees might put of these social networking sites, I suggest that their IT departments block access from computers inside the organization’s network.

]]> By: Fard Johnmar http://blog.pharmexec.com/2008/10/10/is-fda-watching-youtube/comment-page-1/#comment-16209 Fard Johnmar Wed, 15 Oct 2008 15:03:51 +0000 http://blog.pharmexec.com/?p=302#comment-16209 George: Very interesting. My feeling is let's not make a mountain out of a molehill. Clearly, FDA is going to monitor any media channel pharma is using to promote its products. It's important to focus on content, not context when evaluating the regulatory risks of specific marketing initiatives. For more on this topic, please see my blog post about the Shire warning letter here: http://tinyurl.com/3v4obc. George:

Very interesting. My feeling is let’s not make a mountain out of a molehill. Clearly, FDA is going to monitor any media channel pharma is using to promote its products. It’s important to focus on content, not context when evaluating the regulatory risks of specific marketing initiatives. For more on this topic, please see my blog post about the Shire warning letter here: http://tinyurl.com/3v4obc.

]]>